UY25032A1 - Procedimiento para preparar una nueva composicion - Google Patents
Procedimiento para preparar una nueva composicionInfo
- Publication number
- UY25032A1 UY25032A1 UY25032A UY25032A UY25032A1 UY 25032 A1 UY25032 A1 UY 25032A1 UY 25032 A UY25032 A UY 25032A UY 25032 A UY25032 A UY 25032A UY 25032 A1 UY25032 A1 UY 25032A1
- Authority
- UY
- Uruguay
- Prior art keywords
- composition
- pharmaceutically acceptable
- compound
- acceptable carrier
- preparing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención describe un procedimiento para preparar una composición farmacéutica de 5-[4-[2-(N-metil-N-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona (Compuesto (I)) en una forma farmacéuticamente aceptable y un vehículo farmacéuticamente aceptable, cuyo procedimiento comprende: (i) preparar una primera composición caracterizada porque la composición es un concentrado del Compuesto (I) en una forma farmacéuticamente aceptable adaptada para ser diluida a fin de proporcionar una composición para administración oral en dosis unitarias y un primer vehículo farmacéuticamente aceptable; (ii) mezclar la primera composición con un segundo vehículo farmacéuticamente aceptable para proporcionar la composición requerida de Compuesto (I). Se ha indicado que una dosis diaria discreta y particular de Compuesto (I) proporciona un efecto especialmente beneficioso sobre el control glicémico y, por lo tanto, es particularmente útil para el tratamiento de la diabetes mellitus.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9711683.4A GB9711683D0 (en) | 1997-06-05 | 1997-06-05 | Composition |
GBGB9712851.6A GB9712851D0 (en) | 1997-06-18 | 1997-06-18 | Composition |
Publications (1)
Publication Number | Publication Date |
---|---|
UY25032A1 true UY25032A1 (es) | 1998-11-26 |
Family
ID=26311662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY25032A UY25032A1 (es) | 1997-06-05 | 1998-06-04 | Procedimiento para preparar una nueva composicion |
Country Status (29)
Country | Link |
---|---|
EP (1) | EP0998284A1 (es) |
JP (1) | JP2001521553A (es) |
KR (1) | KR20010013410A (es) |
CN (3) | CN1526391A (es) |
AP (1) | AP1214A (es) |
AR (2) | AR015120A1 (es) |
AU (1) | AU8215098A (es) |
BG (1) | BG104048A (es) |
BR (1) | BR9810405A (es) |
CA (2) | CA2333352A1 (es) |
CO (1) | CO4940400A1 (es) |
DZ (1) | DZ2510A1 (es) |
EA (1) | EA002384B1 (es) |
GB (1) | GB9711683D0 (es) |
HU (1) | HUP0004070A3 (es) |
ID (1) | ID24264A (es) |
IL (1) | IL133074A0 (es) |
MX (1) | MXPA99011322A (es) |
NO (2) | NO995938L (es) |
NZ (2) | NZ523725A (es) |
OA (1) | OA11306A (es) |
PE (1) | PE78899A1 (es) |
PL (1) | PL337201A1 (es) |
SK (1) | SK164899A3 (es) |
TR (2) | TR200002790T2 (es) |
TW (1) | TW570797B (es) |
UY (1) | UY25032A1 (es) |
WO (1) | WO1998055122A1 (es) |
ZA (2) | ZA9811572B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL351684A1 (en) | 1999-04-23 | 2003-06-02 | Smithkline Beecham Plc | Polymorph of 5−[4−[2− (n−methyl−n−( 2−pyridyl)amino) ethoxy]benzyl] thiazolidine−2,4−dione, maleic acid salt |
BR0009934A (pt) | 1999-04-23 | 2002-06-04 | Smithkline Beecham Plc | Produto farmacêutico |
US20040248945A1 (en) | 1999-04-23 | 2004-12-09 | Smithkline Beecham P.L.C. | Thiazolidinedione derivative and its use as antidiabetic |
GB0021978D0 (en) | 2000-09-07 | 2000-10-25 | Smithkline Beecham Plc | Novel pharmaceutical |
GB0127805D0 (en) * | 2001-11-20 | 2002-01-09 | Smithkline Beecham Plc | Pharmaceutical composition |
GB0129871D0 (en) * | 2001-12-13 | 2002-02-06 | Smithkline Beecham Plc | Novel pharmaceutical |
AU2002350965A1 (en) * | 2001-12-13 | 2003-06-23 | Smithkline Beecham Plc | Toluenesulfonate hydrates of a thiazolidinedione derivative |
GB0129876D0 (en) * | 2001-12-13 | 2002-02-06 | Smithkline Beecham Plc | Novel pharmaceutical |
GB0130509D0 (en) * | 2001-12-20 | 2002-02-06 | Smithkline Beecham Plc | Novel pharmaceutical |
US7435741B2 (en) | 2006-05-09 | 2008-10-14 | Teva Pharmaceutical Industries, Ltd. | 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
EP1854794A1 (en) * | 2006-05-09 | 2007-11-14 | Teva Pharmaceutical Industries Ltd. | 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
WO2015008234A1 (en) * | 2013-07-17 | 2015-01-22 | Glenmark Pharmaceuticals S.A. | Bicyclic heterocyclic compounds as ror gamma modulators |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE186724T1 (de) * | 1987-09-04 | 1999-12-15 | Beecham Group Plc | Substituierte thiazolidindionderivate |
GB9218830D0 (en) * | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
SG47100A1 (en) * | 1994-02-10 | 1998-03-20 | Smithkline Beecham Plc | Use of insulin sensitisers for treating renal diseases |
WO1997005875A2 (en) * | 1995-08-10 | 1997-02-20 | Warner-Lambert Company | A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus |
AU7604596A (en) * | 1995-11-17 | 1997-06-11 | Warner-Lambert Company | A method of treating myotonic dystrophy |
IL120443A (en) * | 1996-03-18 | 2000-07-16 | Sankyo Co | Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis |
WO1998002159A1 (en) * | 1996-07-12 | 1998-01-22 | Smithkline Beecham Plc | Novel treatment of leptine resistance |
-
1997
- 1997-06-05 GB GBGB9711683.4A patent/GB9711683D0/en active Pending
-
1998
- 1998-06-02 IL IL13307498A patent/IL133074A0/xx unknown
- 1998-06-02 JP JP50158799A patent/JP2001521553A/ja not_active Ceased
- 1998-06-02 PL PL98337201A patent/PL337201A1/xx unknown
- 1998-06-02 CN CNA2003101199090A patent/CN1526391A/zh active Pending
- 1998-06-02 MX MXPA99011322A patent/MXPA99011322A/es unknown
- 1998-06-02 NZ NZ523725A patent/NZ523725A/en unknown
- 1998-06-02 HU HU0004070A patent/HUP0004070A3/hu unknown
- 1998-06-02 EP EP98932144A patent/EP0998284A1/en not_active Withdrawn
- 1998-06-02 TR TR2000/02790T patent/TR200002790T2/xx unknown
- 1998-06-02 SK SK1648-99A patent/SK164899A3/sk unknown
- 1998-06-02 CN CN98805686A patent/CN1112926C/zh not_active Expired - Lifetime
- 1998-06-02 WO PCT/EP1998/003478 patent/WO1998055122A1/en not_active Application Discontinuation
- 1998-06-02 CA CA002333352A patent/CA2333352A1/en not_active Abandoned
- 1998-06-02 AP APAP/P/1999/001696A patent/AP1214A/en active
- 1998-06-02 AU AU82150/98A patent/AU8215098A/en not_active Abandoned
- 1998-06-02 BR BR9810405-5A patent/BR9810405A/pt not_active IP Right Cessation
- 1998-06-02 CA CA002292629A patent/CA2292629C/en not_active Expired - Fee Related
- 1998-06-02 ID IDW991520A patent/ID24264A/id unknown
- 1998-06-02 KR KR19997011411A patent/KR20010013410A/ko not_active Application Discontinuation
- 1998-06-02 TR TR1999/02963T patent/TR199902963T2/xx unknown
- 1998-06-02 EA EA199901116A patent/EA002384B1/ru not_active IP Right Cessation
- 1998-06-03 DZ DZ980120A patent/DZ2510A1/xx active
- 1998-06-04 CO CO98031614A patent/CO4940400A1/es unknown
- 1998-06-04 ZA ZA9811572A patent/ZA9811572B/xx unknown
- 1998-06-04 ZA ZA9804826A patent/ZA984826B/xx unknown
- 1998-06-04 AR ARP980102650A patent/AR015120A1/es not_active Application Discontinuation
- 1998-06-04 UY UY25032A patent/UY25032A1/es not_active IP Right Cessation
- 1998-06-04 AR ARP980102649A patent/AR008198A1/es not_active Application Discontinuation
- 1998-06-05 PE PE1998000466A patent/PE78899A1/es not_active Application Discontinuation
- 1998-10-23 TW TW087117536A patent/TW570797B/zh not_active IP Right Cessation
-
1999
- 1999-12-02 OA OA9900267A patent/OA11306A/en unknown
- 1999-12-03 NO NO995938A patent/NO995938L/no not_active Application Discontinuation
- 1999-12-27 BG BG104048A patent/BG104048A/bg unknown
-
2001
- 2001-09-03 NZ NZ513922A patent/NZ513922A/xx unknown
-
2002
- 2002-11-05 CN CN02149972A patent/CN1430959A/zh active Pending
-
2004
- 2004-02-20 NO NO20040738A patent/NO20040738L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY25032A1 (es) | Procedimiento para preparar una nueva composicion | |
MY129897A (en) | Use of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2, 4-dione and metformin for the treatment of diabetes mellitus | |
AP1545A (en) | Hydrochloride salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione. | |
AR030920A1 (es) | Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones | |
BRPI0606768A2 (pt) | forma de dosagem oral compreendendo rosiglitazona | |
BR0114196A (pt) | Formas polimórficas de maleato de 5-[4-[2-[n-metil-n-(2-piridil) amino]etóxi]benzil]tiazolidina-2,4-diona e processo para a preparação das mesmas. | |
MY135973A (en) | Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative | |
AR015894A1 (es) | Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona e insulina para la preparacion de un medicamento y composicion farmaceuticaque contiene dichos compuestos | |
UY25102A1 (es) | Nueva composición para el tratamiento de diabetes mellitus | |
NZ515555A (en) | Treatment of diabetes with thiazolidinedione and sulphonylurea | |
PE108199A1 (es) | Composicion farmaceutica de tiazolidindiona y sulfonilurea | |
AP1715A (en) | The hydrochloride salt of 5-[ 4 -[2 -(n-methyl-n- (2-pyridyl) amino) ethoxy]benzyl]thiazolidine -2,4-dione | |
BR0112981A (pt) | Sais tartarato de derivado de tiazolidinadiona | |
AU2002343052A1 (en) | Rosiglitazone edisylates and their use as antidiabetics | |
BR0111536A (pt) | Sal de tiazolidinediona para tratamento de diabetes mellitus | |
GB0021784D0 (en) | Novel pharmaceutical | |
AP2003002737A0 (en) | Tartrate salts of thiazolidinedione derivatives | |
CY1107767T1 (el) | Παραγωγο θειαζολιδινοδιονης και χρηση αυτου σαν αντιδιαβητικο | |
NZ524933A (en) | Sodium salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and pharmaceutical composition thereof | |
BR0112982A (pt) | Sal tartarato de derivado de tiazolidinadiona | |
WO2003099337A3 (en) | Inclusion complexes of rosiglitazone | |
BR0112983A (pt) | Sais tartarato de derivado de tiazolidinodiona | |
NZ510672A (en) | Composition comprising 5-[4-[2-(N-Methyl-N-2-Pyridyl)Amino)-Ethoxy]Benzyl]Thiazolidine-2,4-Dione |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
VENC | Patent expired |
Effective date: 20180604 |